About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, January 14th, 2014

The QualityStocks
Daily Stock List


UMAX Group Corp. (UMAX)

We are reporting on UMAX Group Corp. (UMAX), here at the QualityStocks Daily Newsletter.

UMAX Group Corp. is a nutraceutical company based in Los Angeles, California. UMAX’s dedication is to providing only authentic, potent, and ultra-pure nutritional supplements. The Company’s product line includes supplements for weight loss, colon health, sexual health, general health, and vitality. UMAX provides a wide-ranging line of natural and organic nutrition and dietary supplements. UMAX Group conducts their business as UMAX Nutrition. The Company lists on the OTC Bulletin Board.

The Company’s products include UpriteXXL - an all natural herbal male enhancement supplement.  In addition, their products include Green Coffee Bean Extract; it contains only 100 percent pure Green Coffee Bean Extract, with no added fillers or binders.

Furthermore, their products include Raspberry Ketone. This is a potent formula that has other ingredients such as African Mango, Acai, Resveratrol, Apple Cider Vinegar, and Grapefruit. UMAX offers their products by way of their online website.

UMAX Group announced an update in November of 2013. UMAX Nutrition's multi-dimensional marketing plan will now include Radio, Print, TV, as well as Internet campaigns. Their marketing plan will concentrate on developing a weight loss system with a leading physician, specializing in obesity and weight management.

UMAX’s new strategic partners are Ship-Right Solutions, and Core-Logix. Ship-Right Solutions will now fulfill UMAX's domestic and international orders from their facilities throughout the United States.  Ship-Right Solutions is a full service third party logistics firm. Their specialty is direct to consumer shipments, customer support, and data management.

Core-Logix is a fully integrated and dedicated inbound call center, with a team of live operators. Core-Logix will now receive all inbound sales requests from UMAX’s Radio and Television campaigns.

UMAX was also in discussions with leading media marketing companies, which specialize in direct response, with a focus on weight loss systems, bringing awareness, visibility, and sales to UMAX’s new and existing products. UMAX started their radio campaign by targeting large cities on the East and West Coasts and certain cities in the Midwest.

Additionally, UMAX will be reintroducing a popular male enhancement product that has already seen major success in these markets. UMAX’s corporate mission is to become the recognized leader in providing all natural to meet customers’ needs to maintain a quality, healthy lifestyle.

UMAX Group Corp. (UMAX), closed Tuesday's trading session at $0.42, down 16.00%, on 13,699 volume with 8 trades. The average volume for the last 60 days is 16,423 and the stock's 52-week low/high is $0.2109/$0.66.

BioRestorative Therapies, Inc. (BRTX)

Streetwise Reports, Investor Ideas, ProActive Capital, and The Online Investor reported earlier on BioRestorative Therapies, Inc. (BRTX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

BioRestorative Therapies, Inc. is a life sciences company headquartered in Jupiter, Florida. The Company is focusing on adult stem cell-based therapies for various personal medical applications. BioRestorative Therapies develops products and medical procedures using cell and tissue protocols, chiefly involving adult stem cells. In addition, they also offer plant stem cell-based facial creams and beauty products under the Stem Pearls® brand. BioRestorative Therapies lists on the OTC Bulletin Board.

The Company’s goal is to become a leader in providing medical procedures using cell and tissue protocols, primarily involving adult stem cells (non-embryonic), and allowing patients to undergo minimally invasive cellular-based treatments.

BioRestorative’s products and medical procedures include brtxDISC™ (Disc Implanted Stem Cells); ThermoStem®, and brtx-C Cosmetic. brtxDISC™ (Disc Implanted Stem Cells) is an investigational non-surgical treatment for bulging and herniated lumbar discs intended for patients who have failed non-invasive procedures and face the prospect of surgery.

ThermoStem® is a treatment using brown fat stem cells, which is under development for metabolic disorders; this includes diabetes and obesity. brtx-C Cosmetic is founded on the development of a human cellular extract that has been demonstrated in ‘in vitro’ skin studies to increase the production of collagen and fibronectin.

In early December 2013, BioRestorative Therapies announced that their ThermoStem® program has led to a study to be published in the peer-reviewed journal Stem Cells. The newly identified human adult brown fat stem cells discussed in the study have the potential to lead to the development of a cell-based method for the treatment of type 2 diabetes and obesity.

The results of this study show for the first time that a multipotent stem cell population exists in human adult brown adipose depots and that this population can be differentiated into metabolically functional brown adipocytes. Brown adipocytes are key cells involved in energy homeostasis and metabolism. In humans, loss of brown adipose (fat) activity may account for the lower metabolism frequently associated with diabetes and obesity.

BioRestorative Therapies, Inc. (BRTX), closed Tuesday's trading session at $0.7499, down 3.33%, on 15,100 volume with 10 trades. The average volume for the last 60 days is 16,395 and the stock's 52-week low/high is $0.33/$1.95.

Islet Sciences, Inc. (ISLT)

FeedBlitz, Prof. Stocks, and Proactivecrg reported earlier on Islet Sciences, Inc. (ISLT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Based in Raleigh, North Carolina, Islet Sciences, Inc. is a biopharmaceutical company that lists on the OTC Markets’ OTCQB. The Company is developing novel technologies for the diagnosis and treatment of patients suffering from metabolic diseases. The Company has entered into a number of collaborations with prestigious diabetes research groups. These collaborations allow Islet to pursue a broad array of cell transplantation technologies.

Islet Sciences’ mission is to become the leading innovator, developer and provider of therapeutics and diagnostics for diabetes. The Company reported in December 2013 that they are consolidating operations centrally under a one-company/one-pipeline strategy as they move away from independently managed programs.

The Company’s belief is that their xenotransplantation approach and proprietary microencapsulation technology will overcome many obstacles to cell transplantation and may enable insulin-dependent diabetes patients to become free of insulin injections. Islet’s approach is founded on the technologies of xenotransplantation and microencapsulation. Xenotransplantation, specifically, the use of porcine islet cells, provides an essentially unlimited supply of cells for transplantation. Microencapsulation involves the surrounding of islet cells with a highly biocompatible biopolymer called alginate, which reduces the host's immune response to the implanted material.

Islet Sciences is developing their first product. This is microencapsulated porcine islets for injection into the abdominal cavity. The Company’s technologies are undergoing development to optimize islet survival and functionality during the manufacturing process.

Last week, Islet Sciences announced that Dr. Eric Barnett, Executive Vice President at Piedmont Pharmaceuticals, LLC, was elected to the Islet Sciences Board of Directors. Dr. Barnett is an experienced life-science executive, doctor of medicine, and chartered accountant. He is responsible for Business Development and Marketing at Piedmont Pharmaceuticals, to develop and execute Piedmont’s long-term growth strategies including launching new brand initiatives. Previously, Dr. Barnett was Vice President at GlaxoSmithKline and member of the clinical executive committee where he was responsible for financial capital management of the global research and development clinical portfolio.

Islet Sciences, Inc. (ISLT), closed Tuesday's trading session at $0.90, up 28.57%, on 88,740 volume with 47 trades. The average volume for the last 60 days is 6,803 and the stock's 52-week low/high is $0.15/$4.75.

North American Oil & Gas Corp. (NAMG)

SUPERSTOCKPLAYS reported this week on North American Oil & Gas Corp. (NAMG), Penny Stock Professor, Investors Alley, PennyStocks24, Orbit Stocks, MyBestStockAlerts, PremiereStockAlerts, Fast Money Alerts, Penny Stock General, Stock Shock and Awe, FutureMoneyTrends.com did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

North American Oil & Gas Corp. (NAMG) is an oil and gas company that offers oil and gas production services. The Company is focusing on the San Joaquin Basin, onshore California, with existing foundation assets targeting exploration and exploitation of high impact oil and gas projects located close to infrastructure and existing discoveries. NAMG has identified 14 prospects targeting P50/P10 gross resources of 24/81mmboe gross. They are targeting near term oil with a high chance of success for reserves and production. The Company’s projects are concentrated in the southern part of the San Joaquin Basin providing a technical and operational focus to their activities.

North American Oil and Gas Corporation (NAMG) is an earlier merger (December 5, 2012) between OTCBB-listed company Calendar Dragon, Inc. and a private oil and gas company – Lani, LLC. NAMG’s shares trade on the OTC Bulletin Board. The Company has their headquarters in Ventura, California.

NAMG seeks to partner with companies to develop extensions to existing producing fields and additionally to establish new development opportunities supported by high quality 3-D seismic analysis. The Company has a balanced portfolio of multiple projects targeting near term oil opportunities and moderate to high impact exploration positioned near existing discoveries.

NAMG’s acreage position is approximately 8,000 gross acres (approximately 5,000 net acres) with large exploration upside. The Company has three major project areas, shallow (and deep), The Tejon Main prospect, the Tejon Extension prospect, and the White Wolf prospect.

The Company holds a 40 percent working interest in the Tejon Footwall Main project, and are the operators. This prospect has a gross acreage of 2,874 and net acreage of 2,600. They hold a 75 percent working interest in the Tejon Extension project, and are the operators of this prospect. The Tejon Extension project has a gross acreage of 546 and net acreage of 346. In addition, NAMG, the operator, holds a 50 percent working interest in the White Wolf project. NAMG is participating in more than 4,600 gross acres.

NAMG announced in September 2013 that they completed an exhaustive analysis on the 3D survey covering their 3,429 gross acres (2,946 net acres) Tejon Area totals. The prospects include five target horizons: the Eocene, Vedder, Jv, Olcese, Reserve and Transition Zone. They completed mapping and volumetric analysis of the 14 prospects previously identified, further refining their extent and reducing their associated technical risk. This work has enabled NAMG to prioritize their prospect inventory in terms of geologic risk, resource potential, drilling difficulty, and permitting issues.   

North American Oil & Gas Corp. (NAMG), closed Tuesday's trading session at $0.32, down 2.08%, on 481,444 volume with 163 trades. The average volume for the last 60 days is 525,188 and the stock's 52-week low/high is $0.285/$1.67.

Sterling Consolidated Corp. (STCC)

Damn Good Penny Picks and Penny Stock Newsletter reported this week on Sterling Consolidated Corp. (STCC), StockRockandRoll, StockBomb.com, Investor News Source, and PennyStocks24 did earlier, and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTC Bulletin Board, Sterling Consolidated Corp., via their wholly-owned subsidiary, Sterling Seal and Supply, has been a leading supplier of hydraulic and pneumatic seals to the automotive and industrial marketplace for more than 40 years. Sterling Consolidated’s intention is to be an active and strategic consolidator of small- and mid-sized businesses within the highly-fragmented, multi-billion dollar seal industry.  Sterling Consolidated is based in Neptune, New Jersey.

Currently, the Company serves more than 3,000 customers. Sterling offers acquisition targets a unique growth opportunity and competitive advantage through logistical expertise, strong regional branding, as well as industry-specific distribution centers.

Sterling Consolidated announced in October 2013 that they fully integrated their most recent acquisition, Superior Seals and Service. The acquisition of Superior Seals and Services provides Sterling with an increased customer base and expedited delivery options to new and existing customers. Sterling has integrated their business and accounting procedures with their new strategic North Carolina location, since the purchase of their recent acquisition. This integration has exposed established customers to new products. This has led to greater revenue and enhanced service with new business stemming from Sterling's accounts.

This past November, Sterling Consolidated issued a letter by Chairman Mr. Angelo DeRosa updating shareholders on the Company's progress in 2013. Mr. DeRosa stated that throughout 2013, the management team was focused on sales and efficiencies. The organic sales of the Company rose in 2013; the Company’s gross margins improved over 12 percent in 2013 alone. He indicated that better management of inventory and consolidation of purchasing contributed significantly.

Last week, Sterling Consolidated announced that following the Company’s acquisition and continuing growth, their customer base increased 5 percent during the full year of 2013. The Company has continued to expand their O ring distribution network in the Northeast; this has led to a considerable increase in their customer base. Company Management indicated that they are confident that their competitive offerings have positioned Sterling Consolidated for continued growth and expect similar, if not greater results in 2014.

Sterling Consolidated Corp. (STCC), closed Tuesday's trading session at $0.15, down 11.76%, on 343,743 volume with 89 trades. The average volume for the last 60 days is 68,265 and the stock's 52-week low/high is $0.09/$0.30.

Petro River Oil Corp. (PTRC)

Pumps and Dumps, PennyStockPlayers, The Stock Scout, PennyStockClub, Penny Stock Pros, PennyStocks24, and Pennybuster reported earlier on Petro River Oil Corp. (PTRC), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Petro River Oil Corp. is an independent exploration and production company. They concentrate on their oil properties in the Mississippi Lime play in eastern Kansas. The Mississippi Lime play covers approximately 17 million acres in Oklahoma and Kansas, compared to 10- to 15 million acres in the Bakken and 6 million in the Eagle Ford. Petro River Oil has an extensive inventory of low cost, high return development drilling opportunities. Founded in 2011, Petro River Oil is based in Houston, Texas.

Petro River Oil completed several related transactions through which they acquired control of Petro River Oil, LLC (Petro LLC) and Petro’s wholly-owned subsidiary Petro River Operating, LLC.  Petro River Oil’s specific goals include increasing production through developing their acreage; increasing profitability margins through evaluating and optimizing their production, and executing their business plan to increase property values, reserves, and expanding their asset base. In addition, the Company has substantial acreage and oil reserves in Missouri. Petro River's extensive portfolio includes more than 115,000 net acres of oil and gas assets in Kansas, Missouri and Kentucky.

Petro River Oil is concentrating on developing their recently acquired Mississippi Lime acreage in Kansas and also their heavy oil properties in Missouri and Kentucky. Early reservoir projects in Kansas were focused on proving reserve potential into the Bourbon Arch geological region of the Mississippi Lime play. The production response from this region established migration and asset production potential. Additionally, Petro River Oil engaged an extensive geologic study of the Company’s leasehold position using more than 26,000 producers and 40 acres of a proprietary 3D data set. Their intention is to raise capital to drill several prospective reserve targets.

Petro LLC is an emerging oil and gas producer that controls a substantial acreage position in the Southeast Kansas region of the Mississippi Lime formation. Owing to the acquisition of Petro River Oil, the Company has added 115,000 gross/85,000 net acres to their Oil and Gas portfolio. This includes five producing oil and gas wells in which Petro owns a 50 percent Working Interest (WI) and a 40 percent Net Revenue Interest (NRI).

This has established a foremost presence in the Mississippi Lime play. This acreage is in addition to the Company's present Oil and Gas portfolio. Moreover, Petro River Oil also acquired over 60 square miles of proprietary 3D seismic data over prospective Mississippi Lime acreage in the same region. As part of this acquisition, WI’s in leases in which Petro River Oil already has a stake were acquired from Mega Partners I for approximately 15.5mm shares.

Last month, Petro River Oil announced that, on December 12, 2013, the Company closed a private placement of common stock at $0.08 per share for total gross proceeds of $6.5 million. Moreover, they issued a warrant to purchase additional common stock at a strike price of $0.1356 prior to December 12, 2015. All of the offering was purchased by Petrol Lakes Holding Ltd., a newly formed investment group based in China with strategic ties to the country's oil and gas industry. The proceeds will be used to fund development of Petro River's extensive portfolio.

Petro River Oil Corp. (PTRC), closed Tuesday's trading session at $0.115, down 3.04%, on 1,324,783 volume with 71 trades. The average volume for the last 60 days is 792,074 and the stock's 52-week low/high is $0.019/$0.56.

Elite Pharmaceuticals, Inc. (ELTP)

SmallCap Network, PennyStocks24, Pennybuster, SmarTrend Newsletters, Greenbackers, OTCBB Journal, First Penny Picks, and Real Pennies reported on Elite Pharmaceuticals, Inc. (ELTP), and we choose to highlight the Company today, here at the QualityStocks Daily Newsletter.

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company listed on the OTC Bulletin Board. The Company develops oral sustained and controlled release products. Elite Pharmaceuticals operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, New Jersey. Their corporate strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry.  Elite Pharmaceuticals has their corporate headquarters in Northvale, New Jersey.

The Company has six commercial products currently selling, an additional product approved and soon to be launched, 11 approved products pending manufacturing site transfer, and two additional products under review pending approval by the Food and Drug Administration (FDA).

Elite Pharmaceuticals announced in October 2013 the signing of a Manufacturing and License Agreement with Epic Pharma, LLC. Epic Pharma will have the right to manufacture, market, and sell in the U.S. and Puerto Rico a number of generic products owned by Elite Pharmaceuticals. Elite will receive a license fee and milestone payments. 

Elite Pharmaceuticals’ lead pipeline products include abuse resistant opioids utilizing their patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain. They address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse.

Elite Pharmaceuticals also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Furthermore, Elite has partnered with Epic Pharma for the manufacturing and distribution of eleven approved products pending manufacturing site, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the U.S. market and its territories.

In early December 2013, Elite Pharmaceuticals announced the first dosing of a pilot bioequivalence study in healthy volunteers for ELI-201. This is the Company's twice daily abuse deterrent oxycodone/naltrexone product. Elite met the goal of starting the bio study for ELI-201 in December. A pivotal bioequivalence study for a second abuse deterrent product is scheduled to begin dosing this month, and the pivotal bioequivalence study for ELI-201 is scheduled to begin dosing in March 2014. The bioequivalence studies for these opioid abuse deterrent products are taking place under the direction of Camargo Pharmaceutical Services.

Elite Pharmaceuticals, Inc. (ELTP), closed Tuesday's trading session at $0.1895, up 8.41%, on 13,331,704 volume with 957 trades. The average volume for the last 60 days is 1,699,774 and the stock's 52-week low/high is $0.0631/$0.20.

BrainStorm Cell Therapeutics, Inc. (BCLI)

IRGnews Alert, AllPennyStocks, FeedBlitz, Pumps and Dumps, StockMister, Stock Stars, and OTCPicks reported earlier on BrainStorm Cell Therapeutics, Inc. (BCLI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Bulletin Board, BrainStorm Cell Therapeutics, Inc. is a leading developer of adult stem cell technologies for neurodegenerative diseases. A biotechnology company, BrainStorm engages in developing first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. Brainstorm Cell Therapeutics is currently conducting a Phase IIa ALS clinical trial with NurOwn™ at the Hadassah University Medical Center in Jerusalem. In addition, the Company plans to commence a Phase II clinical trial in the United States in early 2014, pending Food and Drug Administration (FDA) approval. BrainStorm Cell Therapeutics has their corporate headquarters in New York, New York.

The Company holds the rights to develop and commercialize their NurOwn™ technology via an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn™ was granted Orphan Drug designation by the US FDA and the European Commission (EC).

NurOwn™ is a proprietary, first-of-its-kind technology that induces autologous bone marrow-derived Mesenchymal Stem Cells (MSCs) to secrete Neurotropic Factors (NTF). The NurOwn™ treatment approach is to transplant these “MSC-NTF” cells back into the patient at or near the site of damage, in the spine and/or muscles.

Last week, the Company announced that they received notification from the European Patent Office (EPO) of their intention to grant BrainStorm’s patent application No. EP06766101.7 entitled "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases." The patent relates to the method of production of BrainStorm’s proprietary stem cells induced to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases. Their proprietary NurOwn™ stem cell therapy underwent development from this differentiation method. BrainStorm Cell Therapeutics is the exclusive worldwide licensee of these technologies from Ramot, where they were developed by Professors Daniel Offen and Eldad Melamed.

Yesterday, BrainStorm Cell Therapeutics announced that they received a Notice of Allowance from the U.S. Patent Office for their "Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases" (serial number 11/727,583) patent application. The Company, pending approval from the FDA, is presently preparing for their forthcoming multi-center Phase II trial in the United States with their proprietary NurOwn™ stem cell therapy.

BrainStorm Cell Therapeutics, Inc. (BCLI), closed Tuesday's trading session at $0.22, even for the day, on 323,366 volume with 35 trades. The average volume for the last 60 days is 370,188 and the stock's 52-week low/high is $0.1026/$0.27.

Nuvilex, Inc. (NVLX)

Stock Market Media Group, Greenbackers, OTCJournal, smartOTC, PennyStocks24, Pumps and Dumps and AllPennyStocks reported this month on Nuvilex, Inc. (NVLX), and we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Founded in 1996, Nuvilex, Inc. is a global biotechnology company based in Silver Spring, Maryland. The Company is focusing on developing and preparing to commercialize treatments for cancer, diabetes, as well as other diseases founded on the live, therapeutically valuable, encapsulated cells platform. Nuvilex provides live, therapeutically valuable, encapsulated cells and services for research and medicine. The Company’s shares trade on the OTCQB.

Nuvilex is leveraging their cancer biology and clinical oncology research experience and expertise, especially for use in oncology treatments, in addition to initiating oncology applications of medical marijuana.

The live-cell encapsulation technology that Nuvilex employs is a way to enclose living cells in protective “cocoons” approximately the size of the head of a pin. The Company does not encapsulate drugs, but living cells. Each capsule can enclose approximately 10,000 cells. This number can vary contingent upon the size of the cells encapsulated. The cell encapsulation technology used by the Company can be classified as a “platform” upon which treatments for different indications may be built.

Nuvilex’s live-cell encapsulation is different from that done by others; the capsules that enclose the cells are made chiefly of cellulose; others use substances such as alginate (a seaweed derivative), agarose, or chitosan, among other substances. In addition, Nuvilex’s pancreatic cancer treatment consists of the use of a proprietary cellulose-based live-cell encapsulation technology together with the long-known and extensively used anticancer drug ifosfamide (IFEX®).

Nuvilex announced in 2013 that they are focusing on positioning their subsidiary, Medical Marijuana Sciences, Inc. (MMS), as a leader among entities in the medical marijuana field. This is by virtue of their objective of using Cannabis constituents in the development of treatments for brain and pancreatic cancer. Nuvilex is developing a treatment for advanced, inoperable pancreatic cancer, via their subsidiary Austrianova Singapore (ASPL). This involves using their proprietary cell encapsulation technology together with the anticancer drug, ifosfamide (IFEX®).

Dr. Mark L. Rabe was named as Chairman of the Scientific Advisory Board (SAB) for Medical Marijuana Sciences (MMS) in late 2013. Dr. Rabe is a well-known figure in the medical marijuana industry. Last week, Nuvilex announced that Richard M. Hyslop, Ph.D. agreed to join the Scientific Advisory Board of MMS, a wholly-owned subsidiary of Nuvilex. Dr. Hyslop is the Professor of Chemistry and Biochemistry at the University of Northern Colorado. He is the first member of the Scientific Advisory Board of MMS recruited by the Board's Chairman, Mark L. Rabe, MD.

Nuvilex, Inc. (NVLX), closed Tuesday's trading session at $0.134, down 0.37%, on 2,221,620 volume with 325 trades. The average volume for the last 60 days is 1,797,081 and the stock's 52-week low/high is $0.025/$0.22.

Transgenomic, Inc. (TBIO)

SmarTrend Newsletters reported recently on Transgenomic, Inc. (TBIO), MicroCap Gems did previously, and we report on the Company today, here at the QualityStocks Daily Newsletter.

Based in Omaha, Nebraska, Transgenomic, Inc. is a global biotechnology company. The Company is advancing personalized medicine in cardiology, oncology, and inherited diseases via diagnostic tests and clinical and research services. Transgenomic has three complementary business divisions: Patient Testing, Biomarker Identification, and Genetic Assays and Platforms. The Company’s shares trade on the OTC Markets’ OTCQB.

Transgenomic’s three complementary business divisions provide specialized diagnostic tests, contract research services for drug development, and equipment, reagents, and other consumables. In addition, the Company is a global leader in cardiac genetic testing with a family of innovative products. These include their C-GAAP test, designed to detect gene mutations that indicate cardiac disorders, or which can lead to serious adverse events.

Transgenomic specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders. The Company is also a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development. Furthermore, Transgenomic produces equipment, reagents, and other consumables that give power to clinical and research applications in molecular testing and cytogenetics.

At the beginning of November 2013, Transgenomic announced that they entered into a collaboration agreement with PerkinElmer, Inc. (PKI) to market and distribute Transgenomic’s oncology diagnostic test portfolio of products in territories outside the U.S.  PKI is a worldwide leader focused on improving the health and safety of people and the environment.

Under the terms of the agreement, effective January 1, 2014, PerkinElmer has the non-exclusive right to commence sales, marketing, distribution, as well as field service activities on a global basis (excluding the U.S.) for Transgenomic’s line of molecular diagnostic oncology products, including CRC RAScan™ and ACE™ kits, for use on the PerkinElmer LabChip® MultiDx platform. The CRC RAScan™ provides a single kit solution for detecting KRAS and NRAS genetic mutations that are highly relevant when considering administration of select EGFR inhibitor therapies associated with metastatic colorectal cancer.

Additionally, in November, Transgenomic announced that Mr. Stephen R. Miller was named Senior Vice President and General Manager, Patient Testing. Mr. Miller brings more than 22 years of experience in the diagnostics and biotechnology industries to Transgenomic. He has a proven record of accomplishment commercializing molecular diagnostic tests on a worldwide basis. Most recently, he provided commercial and strategic consultancy services to an array of diagnostics companies, including Transgenomic.

Transgenomic, Inc. (TBIO), closed Tuesday's trading session at $0.48, up 4.35%, on 130,307 volume with 30 trades. The average volume for the last 60 days is 145,308 and the stock's 52-week low/high is $0.302/$0.73.


The QualityStocks
Company Corner


The Aristocrat Group Corp. (ASCC)

The QualityStocks Daily Newsletter would like to spotlight The Aristocrat Group Corp. (ASCC). Today, The Aristocrat Group Corp. closed trading at $0.1079, up 2.86%, on 227,426 volume with 12 trades. The stock’s average daily volume over the past 60 days is 227,426, and its 52-week low/high is $0.055/$1.25.

Aristocrat Group Corp. reported today that it is sponsoring one of the elite social events in the nation’s fifth-largest metropolitan area, further expanding RWB Vodka’s marketing initiative. RWB Vodka is an official sponsor this week’s Preview Party for the Houston Press Artopia event. The Preview Party is expected to include a number of Houston’s most recognizable citizens while featuring extensive local media coverage in a top 10 U.S. media market.

The Aristocrat Group Corp. (ASCC) is a brand management company focused on providing premiere luxury goods through continual innovation. Luxuria Brands, a subsidiary of The Aristocrat Group, has been established to identify and promote unique brands that have mass market appeal across a diverse demographic.

Luxuria Brands is primarily concentrated on distilled spirits industries, with an initial focus on Vodka branding and marketing. The worldwide distilled spirits market is currently worth about $263 billion. In the U.S. alone, Vodka sales between 2004 and 2009 grew 25% from 13.9 million cases to 58.4 million cases. The clear liquor now accounts for almost a third of all distilled spirits consumed and continues to rise in popularity.

The Aristocrat Group is also pursuing opportunities in the women’s lifestyle industry. The World Bank recently estimated that the earning power of women will reach $18 trillion by 2014, which is twice the estimated 2014 GDP of China and India combined. The Aristocrat Group is working to bring fresh, innovative prenatal and postpartum solutions to women who are looking for a more comprehensive approach to wellness.

The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. The company aims to take a leadership position in multiple growing markets that offer opportunities for partnership, sponsorship, and brand awareness activities. The Aristocrat Group is leveraging the marketing strengths of its team of experts to grow boutique products into powerful, recognizable brands. Disclaimer

The Aristocrat Group Corp. Company Blog

The Aristocrat Group Corp. News:

ASCC: RWB Vodka Sponsoring Upscale Social Event in Houston

ASCC: Study Shows Consumers Demand Premium Spirits

ASCC Adds Major Retailer to Sell Its Premiere Spirit

NeuroMama Ltd. (NEROE)

The QualityStocks Daily Newsletter would like to spotlight NeuroMama Ltd. (NEROE). Today, NeuroMama Ltd. closed trading at $7.50, even for the day. The stock’s average daily volume over the past 60 days is 81, and its 52-week low/high is $5.00/$28.00.

NeuroMama, Ltd. reported today that on Thursday, January 09, the reception for Exhibitors and visitors of CES, featuring a fascinating Cirque Style Production by Award Winning production team Aces Of Acts saw a performer seriously injured as a cable snapped during the performance. NeuroMama, Ltd. has documented the fall in its 3 camera video-shoot of the event, while shooting the NeuroMama.com Search Engine TV commercial.

NeuroMama Ltd. (NEROE) utilizes high quality neural technology to provide super-accurate search returns and power a suite of products including a web search engine, mobile app, more than 120 social networks, email service, finance center, kids zone, and more. The company is also developing the Eurasia Resort/Convention, Retail/Sport and Entertainment Complex in Las Vegas, Nevada, and is highly engaged in international multi-language streaming media distribution via TVIMama.com, Xtreme Sports production, and network/cable distribution.

NeuroZone is just one example of the numerous initiatives underway to expand NeuroMama’s brand and influence. This virtual mall will leverage all the promotional, marketing, and technologic power invested in NeuroMama’s entire stable of highly integrated, symbiotically compatible projects and strategic relationships to create the world’s first, and to date only, viable competitor to mega online retailers like Amazon and eBay. NeuroZone will provide unlimited branding opportunities for NeuroMama’s internet platform, products and services.

NeuroMama recently acquired an extensive library of entertainment assets, which includes a variety of shows, feature films, television pilots, and more. Valued at approximately $100 million dollars, this content library can be rented, liscenced and distributed an infinite number of times. The company is currently deploying an advanced, next-generation Internet Content Distribution Platform (CDP) designed to offer e-commerce merchants and entertainment programmers the most secure, fastest, and robust digital delivery system yet developed.

Other Neuromama.com platform products include NeuroMANIA.com, a child-and-parent friendly hub with 120+ social networks themed to professional and personal interests; and TVIMama.com, video-on-demand streaming and broadcasting of live television. Notably, users of the NeuroMama.com all-in-one internet platform now are earning free breathtaking luxury vacations and free magnificent international cruises with the web's premiere frequent searcher/shopper user loyalty program.

NeuroMama’s team of forward-thinking individuals have engineered an all-encompassing platform from the ground up to take maximum advantage of the last decade's advances in Web crawling, data storage and management, content comparison, analysis and sorting. With numerous opportunities to further expand in the booming Internet market, NeuroMama is well positioned to fully capitalize on its advanced neural technology. Disclaimer

NeuroMama Ltd. Company Blog

NeuroMama Ltd. News:

CES Event Showcasing Intelligent Search Engine, Online Retail Platform and Advertising Opportunities, Reception Act Performer Fall and Serious Injuries Documented

NeuroMama, Ltd. 10Q Will Be Filed In Days. Filing Is Late To Preserve $17MM Asset

NeuroMama's Global Enterprises at International CES

OBJ Enterprises, Inc. (OBJE)

The QualityStocks Daily Newsletter would like to spotlight OBJ Enterprises, Inc. (OBJE). Today, OBJ Enterprises, Inc. closed trading at $0.235, off by 6.04%, on 357,477 volume with 75 trades. The stock’s average daily volume over the past 60 days is 46,633, and its 52-week low/high is $0.22/$0.36.

OBJ Enterprises, Inc., in its continuing efforts to expand its roster of titles in the $93 billion mobile gaming market, Obscene Interactive, the company's games division has engaged new partnership and acquisition targets specializing in educational games. "As we expand our Novalon Games brand, we’re looking for potential breakout hits that expand the public’s understanding of what a game can do for you,” said OBJE CEO Paul Watson.

OBJ Enterprises, Inc. (OBJE) utilizes a powerful joint-venture partnership model to work alongside industry experts and universities to develop educational and popular gaming applications for the digital gaming market, the fastest-growing segment of the global IT industry. The company’s operating subsidiary, Obscene Interactive, is focused on developing innovative social gaming solutions to capitalize on the burgeoning mobile app marketplace, as well as the latest advances in media distribution platforms and advertising placement within apps.

The global gaming industry is predicted to top $66 billion in 2014. As global demand for engaging new gaming content grows with advancements in technology, OBJ Enterprises is pursuing acquisitions of emerging game development companies with portfolios of progressive technology assets such as cloud computing, discrete product placement, and micro-transactions to capitalize on the explosion in console, smartphone, and tablet usage across the globe.

Leveraging innovative and proactive partners who share the company’s vision to create next-generation digital games, OBJ Enterprises has demonstrated its invaluable ability to identify both current gaming trends and keep pace with the industry’s constant evolution. The company is constantly working on new ways to capitalize on emerging gaming trends such as biometric applications - using electronic measurement of unique human characteristics such as fingerprints and irises –for medically themed games, social games, horror games, and more.

Spearheading these growth initiatives is OBJ Enterprises CEO Paul Watson, who has domestic and international experience in fundraising for startups, growth capital, business development, and venture finance. Under his leadership and backed by a team of highly experienced management, OBJ Enterprises plans to advance its gaming portfolio to include applications in health, safety, educational, corporate, and software training. Disclaimer

OBJ Enterprises, Inc. Company Blog

OBJ Enterprises, Inc. News:

OBJE Opens Talks to Expand Game Portfolio

OBJE: Major Celeb Tweets About Bluff Wars, Mobile Gaming’s Next Big Thing

OBJE Closes in on Game Licensing Agreement

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE). Today, Global Payout, Inc. closed trading at $0.09, on 143,544 volume with 8 trades. The stock’s average daily volume over the past 60 days is 36,939, and its 52-week low/high is $0.03/$0.11.

Global Payout, Inc. announced today that it has received its first contract for 2014, an international client, Younique GmbH of Switzerland. The company is also forecasting that this will be the first of many new contracts and many new international clients expected for both the first quarter of 2014, and throughout the rest of the year. Global Payout also announced that they are expecting 2014 to become their breakout year in number of new clients, the number of services sold, the number of payment cards issued, and in the amount of revenues earned.

Global Payout, Inc. (GOHE) specializes in customized payment solutions for businesses and organizations worldwide. The company’s global network of banks and processing partners enable companies and organizations to efficiently deploy a customized payment solution configured specifically for each client. From solving a single payment issue to meeting an entire global payment requirement, Global Payout in conjunction with its partners delivers modular payment solutions.

Global Payout has a product line of prepaid "off the shelf" products that can be utilized or Global Payout can customize payment solutions for qualified businesses. By coupling its network of international banks and third-party processing relationships with an innovative payment platform, Global Payout enables organizations to "plug into" an efficient and cost effective method of paying employees, contractors, investors, and commissioned agents wherever they might be located in the world.

Global Payout began operations as a business to business provider of pre-paid debit cards for payroll and general spend programs. The company then launched a Prepaid Discover® card to meet the demand of its business clients in the United States. As a result of these efforts and with the input of their client base, Global Payout then greatly extended its reach by developing a new proprietary “payment platform” which enables companies and organizations to make necessary payments in every country a company does business. Clients can now make international payments without the need to establish banking relationships in each and every country they do business. Businesses now have an efficient, compliant and simplified system to make their all necessary international payments using Global Payout’s proprietary payment platform.

Global Payout delivers dependable and secure global payment solutions for companies worldwide. This relieves clients of burdensome and time consuming efforts to establish banking relationships everywhere they do business. The company’s “consolidated payment gateway” product can be configured specifically to the needs of each client within a short period of time. Global Payout is led by a management team comprised of pioneers in domestic and international payment delivery solutions. The company is well positioned to leverage their long standing international financial relationships to expand their services and global reach. Even during this expansion, Global Payout remains committed to serving domestic and international clients and providing them with customized one-stop solutions that address each client’s specific payment needs. Disclaimer

Global Payout, Inc. Company Blog

Global Payout, Inc. News:

Global Payout Secures First Of Many New Contracts For 2014 And Predicts Breakout Year

Global Payout and CCS Prepay Announce Joint Venture of International Prepaid Debit Cards

Global Payout, Inc. CEO Featured in Exclusive QualityStocks Interview

Neutra Corp. (NTRR)

The QualityStocks Daily Newsletter would like to spotlight Neutra Corp. (NTRR). Today, Neutra Corp. closed trading at $0.65, on 626,033 volume with 240 trades. The stock’s average daily volume over the past 60 days is 193,104, and its 52-week low/high is $0.1001/$6.50.

Neutra Corp. reported today that, as the $2.3 billion legal cannabis market in the U.S. continues to expand rapidly, as an all-natural wellness provider, NTRR and its joint venture partner Vertigo Technologies, Inc., remain hard at work on a new horticultural system that could revolutionize indoor growing operations across the country.

Neutra Corp. (NTRR) is a multi-faceted early-stage research and development company that’s bringing modern healthy living solutions to various multi-billion dollar markets. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture—one where consumers are demanding access to products that promote health and stave off potential health dangers.

The company’s current product portfolio includes a variety of offerings within the rapidly growing nutraceuticals, food and drug, and environmental sectors. Neutra has established several joint-venture partnerships, and through a joint venture with Air to Surface Solutions, LLC, the company is in developing a new technology to address the problems of plant contaminations and dangerous staph infections (MRSA) among athletes. Neutra is focused on the commercialization of newer, more effective products that eliminate bacteria from the air and tangible surfaces and aims to capitalize on a worldwide boom in these products.

Scientists recently found that topical cannabinoid-based preparations can be effective against MRSA, the deadly antibiotic-resistant flesh-eating disease. Neutra is exploring the potential to bring these therapeutic remedies to the global market. Medicinal cannabis is used to provide relief for patients suffering from the side-effects of chemotherapy and other invasive treatments, as well as pain relief from a range of neurological diseases such as multiple sclerosis.

Neutra has established a partnership with the exclusive Canadian distributor of Purteq. This revolutionary technology is designed to control indoor air contamination, the subsequent microorganism infestations and allergens, and to prevent the spread of diseases such as influenza. Purteq is a patent-pending green technology that works similar to photosynthesis. The product utilizes UV-blue light and water in the air and converts them into microscopic amounts of water, carbon dioxide, and harmless bi-products. This proven technology controls air quality in businesses and homes and opens the path for Neutra to participate in the burgeoning North American air purification market, which is forecast to reach $4.8 billion by 2017.

The global nutraceuticals product market is projected grow to $204.8 billion by 2017. Neutra is positioned for this market with its Pure Plus all-natural weight-loss supplement. The product is based on the company’s groundbreaking Bio-Energy infusion compound, designed to enhance the effects of a supplement’s ingredients to help supercharge the body’s natural weight-loss process and work more quickly and effectively than competing products.

Neutra’s mission is to deliver the highest quality consumer healthy living products while continuing to seek breakthrough advances in the healthy living market. Disclaimer

Neutra Corp. Company Blog

Neutra Corp. News:

NTRR and Partners Ready Turn-Key Solution for Indoor Growers

NTRR Readies Innovative New Products for Booming Colorado Marijuana Industry

NTRR Gains New Ally in the War on Staph Infections

Sohm, Inc. (SHMN)

The QualityStocks Daily Newsletter would like to spotlight Sohm, Inc. (SHMN). Today, Sohm, Inc. closed trading at $0.007, up 89.19%, on 2,285,965 volume with 30 trades. The stock’s average daily volume over the past 60 days is 167,762, and its 52-week low/high is $0.0021/$0.013.

Sohm, Inc. (SHMN) is a globally recognized pharmaceutical manufacturer that develops, manufactures, and distributes generic, private label, and Sohm-innovated pharmaceutical, cosmeceutical, and nutraceutical products. The company exports product worldwide, with a focus on distribution in emerging markets such as Africa, Latin America, and Southeast Asia.

In 2012, Sohm was voted the fastest growing generics prescription drug manufacturer at the 30th All India Conference of National Integrated Medical Association. Committed to being a global leader in improving the health and quality of people’s lives in every corner of the world, the company has U.S. headquarters in Buena Park, CA, with international headquarters located in Ahmedabad, India, and several corporate offices located within the UK and China.

Research and development activities capitalize on the company’s expertise in numerous drug delivery technologies, including solid dosage form, oral-controlled and sustained releases semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and other drug delivery technologies, as well as the application of these technologies to proprietary drug forms.

To ensure regulatory compliance, the company continuously assesses and monitors the output of the existing quality systems, and application of evolving industry guidelines and regulations. Leveraging a global presence, an expanding drug portfolio that covers all major treatment categories, and a respected brand, Sohm is well positioned to continue its rapid growth.. Disclaimer

Sohm, Inc. Company Blog

Sohm, Inc. News:

SOHM Posts FH2013 Financial Results, Provides Full-Year Outlook

SOHM Launches SohMed(TM) Range of Branded OTC Medicines in U.S. Market

SOHM Introduces Second Innovative Skincare Line Product, Salic-2(R) Gel for Acne

GlobalWise Investments, Inc. (GWIV)

The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.10, up 56.25%, on 413,261 volume with 50 trades. The stock’s average daily volume over the past 60 days is 11,116, and its 52-week low/high is $0.041/$0.49.

GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.

GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.

The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.

GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer

GlobalWise Investments Company Blog

GlobalWise Investments News:

GlobalWise Announces Its MarketCommand™ Launch

GlobalWise Investments Reports Financial Results for Third Quarter 2013

GlobalWise Announces the Release of Its New IntellivueGX™ Capture Module

CD International Enterprises, Inc. (CDII)

The QualityStocks Daily Newsletter would like to spotlight CD International Enterprises, Inc. (CDII). Today, CD International Enterprises, Inc. closed trading at $0.10, up 17.65%, on 240,352 volume with 16 trades. The stock’s average daily volume over the past 60 days is 178,965, and its 52-week low/high is $0.041/$0.14.

CD International Enterprises, Inc. (CDII) is a U.S. based company that produces, sources, and distributes industrial commodities in China and the Americas, in addition to providing business and financial consulting services. Headquartered in Deerfield Beach, Florida, with corporate offices in Shanghai, CD International Enterprises’ unique infrastructure provides a platform to expand business opportunities globally.

Through its wholly owned subsidiary, International Magnesium Group, CD International Enterprises owns and operates one of the leading producers of magnesium in the world. International Magnesium Group sources its magnesium from six production facilities in the People's Republic of China, with a combined annual production and distribution capacity of approximately 80,000 metric tons of magnesium ingots and 10,000 metric tons of magnesium powder.

CD International Enterprises also sources, aggregates, and distributes iron ore, manganese ore, and scrap metals for companies located throughout the People’s Republic of China via wholly owned subsidiary CDII Minerals. The scope of CDII Minerals’ services include: purchasing, financing, logistics, quality control, in addition to conducting comprehensive legal, financial, and technical due diligence on suppliers.

The company’s management team possesses the necessary leadership expertise and a solid working knowledge of the unique characteristics of business operations in the U.S., China, Mexico, and South America. Employing a global growth strategy, CD International Enterprises has the unique ability to identify emerging market opportunities and provide comprehensive solutions or services relevant to conducting cross border business. Disclaimer

CD International Enterprises, Inc. Company Blog

CD International Enterprises, Inc. News:

CD International Subsidiary Completes Supply Agreement with Peruvian Mining Company to Distribute Iron Ore

CD International Enterprises and Manali Engineering-India Complete Magnesium Distribution Agreement

QualityStocks Features CD International Enterprises Vice President in Exclusive Interview

Raptor Resources Holdings Inc. (RRHI)

The QualityStocks Daily Newsletter would like to spotlight Raptor Resources Holdings Inc. (RRHI). Today, Raptor Resources Holdings Inc. closed trading at $0.0348, up 15.61%, on 184,148 volume with 7 trades. The stock’s average daily volume over the past 60 days is 95,202, and its 52-week low/high is $0.0018/$0.0395.

Raptor Resources Holdings Inc. (RRHI) is a publicly traded holdings company focused on mineral resource acquisition, exploration, and development. The company currently has two subsidiaries: Mabwe Minerals Inc. (MBMI), a natural resources and hard asset company engaged in the mining and commercial sales of industrial minerals & metals with first focus on barite; and TAG Minerals Inc., a mineral & metal resource acquisition, exploration, and development company with first focus on alluvial surface gold.

Mabwe Minerals has been the focus of the parent company’s efforts the last two years to move into commercial barite production. RRHI shareholders share a common interest with MBMI shareholders in the success of Dodge Mine as the parent company owns 90M shares of MBMI. The Dodge Mine property consists of three hydrothermal mountains representing 123 hectares containing multiple deposits of superior-grade barite, limestone, and talc.

TAG Minerals, along with its indigenous affiliate, TAG Minerals Zimbabwe (Private) Limited, is responsible for alluvial gold production along with the development of greenfield assets targeting bedrock gold and other potential metals & minerals. As MBMI is transitioning into commercial barite production, RRHI will now focus on building assets within TAG Minerals with the intent of moving into commercial production within the next 18 months. TAG Minerals will utilize the latest in Heavy Particle Concentrators (HPC-30/HPC-100) through its relationship with Extrac-TEC whose gold recovery and mineral separation technology captures up to 98% of alluvial gold down to 50 microns. The company is in early stage exploration evaluating potential alluvial sites to ensure they meet the company's criteria for commercial production. Coupled with MBMI's acquisition of WGB Kinsey & Company, TAG Minerals is well positioned to fast track into commercial production once the company has successfully completed its exploratory testing.

RRHI management continues to improve its balance sheet as reflected in the company's SEC 10k filing, including favorable reductions in the company's debt/liabilities and securing 54.4M shares and 14.4M warrants of RRHI from prior employees. The company is committed to growing its asset base in TAG Minerals moving forward. Disclaimer

Raptor Resources Holdings Inc. Company Blog

Raptor Resources Holdings Inc. News:

Mabwe Minerals Receives 10,000 Ton Purchase Order

Mabwe Minerals Launches New Web Site as Affiliate Finalizes Barite Specification Sheets to Commence Barite Qualification

Mabwe Minerals Commences Mining Operations at Dodge Mine

Max Sound Corp. (MAXD)

The QualityStocks Daily Newsletter would like to spotlight Max Sound Corp. (MAXD). Today, Max Sound Corp. closed trading at $0.18, up 5.88%, on 725,696 volume with 60 trades. The stock’s average daily volume over the past 60 days is 317,486, and its 52-week low/high is $0.165/$0.394.

Max Sound Corp. (MAXD) is an HD Audio Technology company with proprietary software that significantly improves the sound quality from virtually any digital or analog source - without increasing file size. Leveraging a strategic software licensing business model, MAX-D’s market is vast and includes improving recorded music, movies, audio books, live streaming, televised events, video games, television network programming, and all audio on mobile devices.

Through Max Sound’s recent acquisition of Liquid Spins, MAX-D has aligned its Technology with a significant audience who purchase music through smart devices. Liquid Spins is a digital media distribution company that has contracts with all major record labels in the United States, and specializes in targeted marketing strategies that focus on selling music in areas where music is not currently sold.

Backed by seasoned management, a competitive advantage, and strong intellectual properties, the company’s MAX-D Audio Process is poised to revolutionize the way consumers listen to media and communicate on their mobile devices. The MAX-D Technology restores audio to the highest quality in real time, while maximizing the output potential of virtually any device - without requiring any equipment change or upgrade in infrastructure.

Consumers have become unaware that they are listening to inferior compressed audio – in much the same way that HD television opened our eyes to a better picture quality, MAX-D opens our ears, to a realistic, true to life listening experience. MAX-D™ is Audio Perfected. Disclaimer

Max Sound Corp. Company Blog

Max Sound Corp. News:

MAX-D HD Audio Hits the Open Road at CES 2014

Max Sound Corporation to Present at 6th Annual LD MICRO Conference on December 3rd

MAX-D® HD Delivers Audio Perfection Experience on Snapdragon® DSP


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Pumps and Dumps





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251